L-C Horn1, S Faber, K Bilek, C Leo. 1. Institute of Pathology, University of Leipzig, Liebigstrasse 26, 04103 Leipzig, Germany. hornl@medizin.uni-leipzig.de
Abstract
PURPOSE: Primary endometrial squamous cell carcinoma (ESCC) are rare but aggressive malignancies. To evaluate therapeutically relevant molecules, ESCC were investigated immunohistochemically. MATERIAL AND METHODS: Eight ESCC were stained with antibodies against estrogen and progesterone receptors, HER-2/neu, and COX-2 followed by semiquantitative evaluation of the staining results. RESULTS: Seven out of eight ESCC were negative for estrogen receptor as well as for HER-2/neu. Four tumors showed positivity for progesterone receptor. All ESCC displayed COX-2 overexpression. CONCLUSIONS: Primary ESCC are probably not under hormonal control of estrogens and lack HER-2/neu expression. Thus, anti-hormonal or antibody therapy with herceptine is not indicated. The use of COX-2 inhibitors might be a therapeutic alternative in ESCC that requires further investigation.
PURPOSE:Primary endometrial squamous cell carcinoma (ESCC) are rare but aggressive malignancies. To evaluate therapeutically relevant molecules, ESCC were investigated immunohistochemically. MATERIAL AND METHODS: Eight ESCC were stained with antibodies against estrogen and progesterone receptors, HER-2/neu, and COX-2 followed by semiquantitative evaluation of the staining results. RESULTS: Seven out of eight ESCC were negative for estrogen receptor as well as for HER-2/neu. Four tumors showed positivity for progesterone receptor. All ESCC displayed COX-2 overexpression. CONCLUSIONS: Primary ESCC are probably not under hormonal control of estrogens and lack HER-2/neu expression. Thus, anti-hormonal or antibody therapy with herceptine is not indicated. The use of COX-2 inhibitors might be a therapeutic alternative in ESCC that requires further investigation.
Authors: P J van Diest; P van Dam; S C Henzen-Logmans; E Berns; M E van der Burg; J Green; I Vergote Journal: J Clin Pathol Date: 1997-10 Impact factor: 3.411
Authors: Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: Aron Goldhirsch; William C Wood; Richard D Gelber; Alan S Coates; Beat Thürlimann; Hans-Jörg Senn Journal: J Clin Oncol Date: 2003-07-07 Impact factor: 44.544
Authors: G Ferrandina; L Lauriola; G F Zannoni; M G Distefano; F Legge; V Salutari; M Gessi; N Maggiano; G Scambia; F O Ranelletti Journal: Br J Cancer Date: 2002-11-04 Impact factor: 7.640
Authors: Peter Rambau; Linda E Kelemen; Helen Steed; May Lynn Quan; Prafull Ghatage; Martin Köbel Journal: Int J Mol Sci Date: 2017-02-27 Impact factor: 5.923